BTN2A1 antagonist (CSL/Olivia Newton-John Cancer Research Institute/Doherty Institute)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameBTN2A1 antagonist (CSL/Olivia Newton-John Cancer Research Institute/Doherty Institute)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionButyrophilin subfamily 2 member A1 inhibitors
TargetsButyrophilin subfamily 2 member A1
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCsl LtdOlivia Newton-John Cancer Research InstituteCopyright The Peter Doherty Institute For Infection And Immunity
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A